GEP-NET Treatment
Apr 26, 2024
Novartis’ LUTATHERA for GEP-NET Treatment: Ray of Hope for Pediatric Patients
2024 could be an eventful year for LUTATHERA and radioligand therapies (RLTs) around their future commercial prospects. On 23rd April 2024, the FDA approved LUTATHERA (also known as lutetium Lu 177 dotatate) for the treatment of pediatric patients of 12 years and older with somatostatin receptor (SSTR)-pos...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
